PUBLIC COMPANY
save$NVSNOVARTIS AG
$NVS141.00-0.04%Basel, CHupdated 2d ago
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
community read0 votes
🐶 often sniffed alongside
top 5pipeline
71
marketed
35
phase 3
7
catalysts ytd
24
approvals ytd
19
recalls ytd
0
Pipeline(71)
view full pipeline →pipeline depth71 products
1Preclinical5Phase 110Phase 27Phase 335Marketed13Unknown
Marketed
(amlodipine besylate + hydrochlorothiazide + valsartan)
Hypertension
Marketed(artemether + lumefantrine)
Malaria
Marketed(brimonidine tartrate + brinzolamide)
Ocular Hypertension
MarketedDiovan
Congestive Heart Failure (Heart Failure)
MarketedDiovan HCT
Hypertension
MarketedEntresto
Cardiovascular Risk Factors
MarketedJadenu
Thalassemia
MarketedKESIMPTA
B-lymphocyte antigen CD20
MarketedMiostat
Miosis
MarketedSpexotras
Low-Grade Glioma
MarketedTobrabact
Bacterial Conjunctivitis
MarketedVijoice
Upcoming
Recent(90d)
view all catalysts →Active trials
- phase3Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
- phase3Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
- —Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
- phase1A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
- —Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France
- phase3Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
- phase4ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)
- —A Study of Ruxolitinib in Patients With Graft-Versus Host Disease
🐶 Hiring Signal
next earnings Oct 27, 2026
Where NOVARTIS AG is staffing up — a leading indicator of pipeline and commercial priorities.
News
no news has mentioned this company yet
Data sources
last refreshed 51m ago
Found something off?
comments(0)
5-min edit window · permanent after that